Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

Current securities

1. Regulation FD DisclosureSep 23, 2026
2. SCHEDULE 13G filingSep 18, 2026
3. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD DisclosureSep 16, 2026
4. Results of Operations and Financial ConditionAug 7, 2026
5. 10-Q filingAug 6, 2026